| 2015 gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative T Neogi, TLTA Jansen, N Dalbeth, J Fransen, HR Schumacher, ... Arthritis & rheumatology 67 (10), 2557-2568, 2015 | 1409 | 2015 |
| A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis Idiopathic Pulmonary Fibrosis Clinical Research Network New England Journal of Medicine 363 (7), 620-628, 2010 | 690 | 2010 |
| Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials JS Sundy, HSB Baraf, RA Yood, NL Edwards, SR Gutierrez-Urena, ... Jama 306 (7), 711-720, 2011 | 665 | 2011 |
| Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly (ethylene glycol)(PEG), in a phase I trial of subcutaneous PEGylated urate oxidase NJ Ganson, SJ Kelly, E Scarlett, JS Sundy, MS Hershfield Arthritis research & therapy 8, 1-10, 2005 | 436 | 2005 |
| Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis: a multicenter, case-control study GS Alarcon, JM Kremer, M Macaluso, ME Weinblatt, GW Cannon, ... Annals of internal medicine 127 (5), 356-364, 1997 | 416 | 1997 |
| Clinical, laboratory, radiographic, and histopathologic features of methotrexate‐associated lung injury in patients with rheumatoid arthritis. A multicenter study with … JM Kremer, GS Alarcón, ME Weinblatt, MV Kaymakcian, M Macaluso, ... Arthritis & Rheumatism 40 (10), 1829-1837, 1997 | 401 | 1997 |
| The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study R Terkeltaub, JS Sundy, HR Schumacher, F Murphy, S Bookbinder, ... Annals of the rheumatic diseases 68 (10), 1613-1617, 2009 | 370 | 2009 |
| Leukemia inhibitory factor, oncostatin M, IL-6, and stem cell factor mRNA expression in human thymus increases with age and is associated with thymic atrophy GD Sempowski, LP Hale, JS Sundy, JM Massey, RA Koup, DC Douek, ... The Journal of Immunology 164 (4), 2180-2187, 2000 | 355 | 2000 |
| Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout PE Lipsky, LH Calabrese, A Kavanaugh, JS Sundy, D Wright, M Wolfson, ... Arthritis research & therapy 16, 1-8, 2014 | 278 | 2014 |
| Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients MS Hershfield, NJ Ganson, SJ Kelly, EL Scarlett, DA Jaggers, JS Sundy Arthritis research & therapy 16, 1-11, 2014 | 271 | 2014 |
| Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the … MC Genovese, K Kalunian, JE Gottenberg, N Mozaffarian, B Bartok, ... Jama 322 (4), 315-325, 2019 | 267 | 2019 |
| Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout JS Sundy, NJ Ganson, SJ Kelly, EL Scarlett, CD Rehrig, W Huang, ... Arthritis & Rheumatism 56 (3), 1021-1028, 2007 | 265 | 2007 |
| Quality of life and disability in patients with treatment-failure gout MA Becker, HR Schumacher, KL Benjamin, P Gorevic, M Greenwald, ... The Journal of rheumatology 36 (5), 1041-1048, 2009 | 208 | 2009 |
| Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol–conjugated uricase) in patients with treatment‐failure gout … JS Sundy, MA Becker, HSB Baraf, A Barkhuizen, LW Moreland, W Huang, ... Arthritis & Rheumatism 58 (9), 2882-2891, 2008 | 192 | 2008 |
| Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial B Combe, A Kivitz, Y Tanaka, D van Der Heijde, JA Simon, HSB Baraf, ... Annals of the rheumatic diseases 80 (7), 848-858, 2021 | 163 | 2021 |
| Symptomatic effects of exposure to diluted air sampled from a swine confinement atmosphere on healthy human subjects SS Schiffman, CE Studwell, LR Landerman, K Berman, JS Sundy Environmental health perspectives 113 (5), 567-576, 2005 | 150 | 2005 |
| Update on nonsteriodal anti-inflammatory drugs SP Ardoin, JS Sundy Current opinion in rheumatology 18 (3), 221-226, 2006 | 146 | 2006 |
| Rilonacept (interleukin‐1 trap) in the prevention of acute gout flares during initiation of urate‐lowering therapy: results of a phase II randomized, double‐blind, placebo … HR Schumacher Jr, JS Sundy, R Terkeltaub, HR Knapp, SJ Mellis, ... Arthritis & Rheumatism 64 (3), 876-884, 2012 | 139 | 2012 |
| Using hyperpolarized 129Xe MRI to quantify regional gas transfer in idiopathic pulmonary fibrosis JM Wang, SH Robertson, Z Wang, M He, RS Virgincar, GM Schrank, ... Thorax 73 (1), 21-28, 2018 | 137 | 2018 |
| Long-term safety of pegloticase in chronic gout refractory to conventional treatment MA Becker, HSB Baraf, RA Yood, A Dillon, J Vázquez-Mellado, FD Ottery, ... Annals of the rheumatic diseases 72 (9), 1469-1474, 2013 | 136 | 2013 |
Dhavalkumar D PatelUCBVerified email at ucb.com
